Clinical Trial Finder Search Results

About the Fight CRC Clinical Trial Finder

This Trial Finder is a one-stop place to find and learn more about high-impact clinical trials for colorectal cancer patients with advanced colon or rectal cancer. Originally created by the late Dr. Tom Marsilje as a curated spreadsheet of trials, the FightCRC’s Trial Finder is a resource to find research studies that are open in your geography, and for which you may be eligible. The current data is now for metastatic, stage IV patients with both MSS and MSI-H status. The list of trials here is sourced from the ClinicalTrials.gov website and curated with Comments and Helpful Links. The searches can be focused on immunotherapy-centered trials and narrowed to studies enrolling patients who already have received immunotherapies.

Medical Disclaimer

The information contained in this website is not intended to recommend the self management of health problems, medical conditions or wellness. It is not intended to endorse or recommend any particular type of medical treatment, physician or treatment facility. Should any reader have any health care related questions, promptly call or consult your physician or healthcare provider. The information contained in this website should NOT be used by any reader to disregard medical and/or health related advice or provide a basis to delay consultation with a physician or a qualified healthcare provider. Fight Colorectal Cancer disclaims any liability based on information provided in this website.

Ubicación

MS status

Recruitment Status

Fase

Drogas

Inmunoterapia previa permitida

NCT ID

Title key word search

Fecha en que se añadió el juicio

From To

View:

Compact Expanded

PDF Excel CSV

NCT ID	Title	Fase	Date Added	Ubicación	Prior IO Allowed	CRC-directed	Status	Drogas	Etiquetas
NCT ID NCT04096417	TitlePemigatinib for the Treatment of Metastatic or Unresectable Colorectal Cancer Harboring FGFR Alterations	Fase Fase 2	Date Added 2019-09-19	Ubicación Arizona, United States Georgia, United States Minnesota, United States North Carolina, United States Tennessee, United States Wisconsin, United States	Prior IO Allowed No	CRC-directed Sí	Status Activo, no recluta	Drogas Pemigatinib	Etiquetas MSS/ MMRp
NCT ID NCT04092673	TitleEstudio de eFT226 en sujetos con tumores sólidos malignos avanzados seleccionados	Fase Fase 1	Date Added 2019-09-17	Ubicación California, United States Michigan, United States Nevada, United States New Jersey, United States New York, United States Ohio, United States Texas, United States Virginia, United States	Prior IO Allowed No	CRC-directed No	Status Reclutamiento	Drogas eFT226, eFT226	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT04085185	TitleEstudio de evaluación de la seguridad, tolerabilidad y eficacia inicial de IBI110 en sujetos con tumores malignos avanzados.	Fase Fase 1	Date Added 2019-09-11	Ubicación China	Prior IO Allowed Sí	CRC-directed No	Status Reclutamiento	Drogas IBI110, IBI110+ Sintilimab, IBI110, Sintilinab	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT04062721	TitleLocal Immunomodulation After Radiofrequency of Unresectable Colorectal Liver Metastases	Fase Fase 1	Date Added 2019-08-20	Ubicación Francia	Prior IO Allowed Sí	CRC-directed Sí	Status Aún no se ha contratado	Drogas Chemotherapy, In situ immunotherapy	Etiquetas MSS/ MMRp
NCT ID NCT04050709	TitleQUILT 3.064: PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid Cancers	Fase Fase 1	Date Added 2019-08-08	Ubicación California, United States	Prior IO Allowed No	CRC-directed No	Status Activo, no recluta	Drogas PD-L1 t-haNK	Etiquetas MSS/ MMRp
NCT ID NCT04046445	TitleEstudio de fase 1b para evaluar ATP128, VSV-GP128 y BI 754091, en pacientes con cáncer colorrectal en estadio IV	Fase Fase 1	Date Added 2019-08-06	Ubicación Arizona, United States California, United States Colorado, United States New York, United States North Carolina, United States Texas, United States Bélgica Alemania Suiza	Prior IO Allowed No	CRC-directed Sí	Status Activo, no recluta	Drogas ATP128, BI 754091, VSV-GP128	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT04041310	TitleNous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors	Fase Phase 1, Phase 2	Date Added 2019-08-01	Ubicación California, United States Florida, United States Indiana, United States Maryland, United States Missouri, United States New York, United States Texas, United States Bélgica Canadá Italia España Reino Unido	Prior IO Allowed No	CRC-directed Sí	Status Activo, no recluta	Drogas	Etiquetas MSI-H/ MMRd
NCT ID NCT04017650	TitleEncorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer	Fase Phase 1, Phase 2	Date Added 2019-07-12	Ubicación Texas, United States	Prior IO Allowed No	CRC-directed Sí	Status Activo, no recluta	Drogas cetuximab, encorafenib, Nivolumab	Etiquetas MSS/ MMRp
NCT ID NCT04014530	TitlePembrolizumab With Ataluren in Patients With Metastatic pMMR and dMMR Colorectal Carcinoma or Metastatic dMMR Endometrial Carcinoma: the ATAPEMBRO Study	Fase Fase 1	Date Added 2019-07-10	Ubicación Países Bajos	Prior IO Allowed No	CRC-directed Sí	Status Reclutamiento	Drogas Ataluren + Pembrolizumab, Keytruda	Etiquetas MSS/ MMRp
NCT ID NCT04009681	TitleEstudio de evaluación de la seguridad y la actividad terapéutica de THOR-707 en sujetos adultos con tumores sólidos avanzados o metastásicos.	Fase Fase 1	Date Added 2019-07-05	Ubicación Arizona, United States Colorado, United States Florida, United States Tennessee, United States Texas, United States Argentina Australia Chile Singapur España	Prior IO Allowed No	CRC-directed No	Status Activo, no recluta	Drogas anti-EGFR antibody, Checkpoint inhibitor, THOR-707	Etiquetas MSI-H/ MMRd, MSS/ MMRp

Showing 171 to 180 of 299 entries